Lv7
4900 积分 2022-07-04 加入
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
1个月前
已完结
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
1个月前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
1个月前
已完结
Mazdutide versus placebo in Chinese adults with type 2 diabetes
1个月前
已完结
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
1个月前
已完结
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial
1个月前
已完结
胆囊良性疾病外科治疗的专家共识（2021版）
4个月前
已关闭
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
